Deal Making

Featured on Deal Making

Hemophilia A-OK! FTC thumbs up effectively closes Roche’s $4.3bn Spark buy
Regulations
Hemophilia A-OK! FTC thumbs up effectively closes Roche’s $4.3bn Spark buyHemophilia A-OK! FTC thumbs up effectively closes Roche’s $4.3bn Spark buy

There is no risk of competitive harm between Roche’s approved hemophila A monoclonal antibody and Spark’s gene therapy candidates, say competition bodies.

byDan Stanton, Editorial director

More from Deal Making

Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.